ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2736

Do Validated Tools of Disease Activity in Ankylosing Spondylitis Measure Fibromyalgia Pain?

Marina N. Magrey1, Sherilyn Diomampo2 and Muhammad Asim Khan3, 1Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, 2MetroHealth Medical Center, Cleveland, OH, 3Medicine/ Rheumatology, Case Western Reserve Univ, Cleveland, OH

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Ankylosing spondylitis (AS), Disease Activity, fibromyalgia and pain

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Concomitant fibromyalgia syndrome (FMS) is a common problem in ankylosing spondylitis (AS) and its recognition is important for optimal management. BASDAI, a disease activity measures for AS has been shown to have poor specificity for AS and was reported to be high in patients with fibromyalgia. Hypothesis guiding our study was that the validated tools of disease activity in AS measure fibromyalgia pain. We studied the association of validated instruments of disease activity in AS with widespread pain index (WPI) and symptom severity score (SS) used in FMS.

Methods: Study was approved by our IRB. We prospectively recruited 62 AS patients ≥18 years of age and meeting the modified New York criteria with grade 3 or 4 sacroiliItis. Demographic and clinical data were collected and stored in Redcap data base. Various questionnaires to assess disease activity and patient reported outcomes in AS were administered to these patients. The frequency of FMS was determined using validated 2010 ACR diagnostic criteria for fibromyalgia. Patient met the fibromyalgia criteria if (i) WPI of ≥ 7 & SS ≥ 5 or WPI 3–6 & SS score ≥ 9,(ii) symptoms were present at a similar level for at least 3 months and (iii) the pain was not attributed to AS by the clinician. ESR and CRP was measured using routine laboratory methods. Descriptive analysis included continuous variables (mean ± SD) and the categorical variables (%). Data were compared by Student’s t-test for continuous variables and chi-square for categorical variables. Linear regression analysis was performed to assess the association between BASDAI, BASMI, ASDAS, Rapid 3, ESR, CRP, WPI and SS scores.

Results: 27/62 (43.5%) patients with AS satisfied the ACR diagnostic criteria for fibromyalgia. Patient demographics and clinical characteristics Table 1.The patients with FMS had significantly higher disease activity as compared to patients without FMS (Table 2). There was no significant relationship of BASDAI, RAPID 3, ASDAS-CRP, physician’s global and patient global scores, ESR, CRP when tested individually with the WPI and SS scores (Table 3).

Conclusion: Despite 43% prevalence of fibromyalgia in our patients with active AS and high disease activity, the validated tools of disease activity in AS did not measure fibromyalgia related pain and symptom severity.

Table 1- Demographics and Clinical Characteristics of Patients

Patients who fulfilled the ACR Diagnostic Criteria for Fibromyalgia N= 27/62 Patients who did not fulfill the ACR Diagnostic Criteria for Fibromyalgia  N=35/62  p- value
Mean age in years  ± SD 48.9 ± 11.2 48.7 ± 13.2 0.94
% African-Americans 63.16 36.84 0.02
%  Females 45 55 0.60
% HLA-B27 positivity 77.7 74.2 0.75
% Acute anterior uveitis 27.2 72.73 0.03
% TNF-i use 51.8 48.5 0.79

Table 2- Comparison of Disease Activity Scores between the two groups

Mean values ± SD Patients with Fibromyalgia Patients without Fibromyalgia p-value
BASDAI 6.8 ± 1.9 3.8 ± 2.2 < 0.0001
RAPID 3 18.1 ± 6.2 10.3 ± 6.7 < 0.0001
ASDAS-crp 4.2 ± 0.9 2.8 ± 0.8 < 0.0001
Physician global 6.5 ± 2.3 4.1 ± 2.1 0.0002
Patient global 7.3 ± 2.2 4.4 ± 2.5 <0.0001
ESR mm/hr 29.5 ± 27.7 15.42 ± 16.3 0.01
CRP mg/dl 2.3 ± 3.5 0.8 ± 0.8 0.01

Table 3- Linear Regression modelling with SS scale and WPI as dependent variable 

Variable BASDAI RAPID 3 ASDAS-CRP ESR CRP
Widespread Pain Index P=0.30 P=0.77 P=0.59 P=0.18 P=0.83
Symptom Severity Scale P=0.15 P=0.64 P=0.86 P=0.82 P=0.96

Disclosure: M. N. Magrey, None; S. Diomampo, None; M. A. Khan, None.

To cite this abstract in AMA style:

Magrey MN, Diomampo S, Khan MA. Do Validated Tools of Disease Activity in Ankylosing Spondylitis Measure Fibromyalgia Pain? [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/do-validated-tools-of-disease-activity-in-ankylosing-spondylitis-measure-fibromyalgia-pain/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/do-validated-tools-of-disease-activity-in-ankylosing-spondylitis-measure-fibromyalgia-pain/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology